Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment

Leuk Res. 2012 Sep;36(9):1208-9. doi: 10.1016/j.leukres.2012.05.024. Epub 2012 Jun 20.

Authors

Fabio Stagno¹, Paolo Vigneri, Alessandra Cupri, Stefania Stella, Francesco Di Raimondo

Affiliation

¹ Department of Clinical and Molecular Bio-Medicine, Sections of Hematology, Oncology and General Pathology, University of Catania - Ferrarotto Hospital, Via Citelli 6, 95124 Catania, Italy. fsematol@tiscali.it

PMID: 22726921
DOI: 10.1016/j.leukres.2012.05.024

No abstract available

Publication types

Comment

MeSH terms

Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Withholding Treatment*

Substances

Piperazines
Pyrimidines